Since B-CLL patients characterized by p53 dysfunction have limited treatment options and poor overall survival [16,18,19], in the first set of experiments we comparatively evaluated the in vitro effect of DCA assessed on B-CLL patient cells characterized by either p53 wild-type or harboring TP53 mutations (Table 1). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.